Prapela
@prapela.bsky.social
We are a Maine-based early-stage company introducing a new therapy for newborns. On April 4, the FDA authorized our pad as the first and only therapeutic vibrational mattress for neonates and infants.
Pinned
Prapela
@prapela.bsky.social
· Apr 17
Prapela, Inc. Granted FDA De Novo for Breakthrough Therapy Helping the Most Vulnerable Victims of our Opioid Epidemic
Prapela’s SVS hospital bassinet pad is the first and only therapeutic medical device to treat opioid exposed newborns with neonatal opioid withdrawal syndrome.
www.einpresswire.com
Proud to share an important milestone in treating opioid-exposed newborns! #Prapela #neonatalcare #medtech
December 4, 2025 at 3:58 PM
Proud to share an important milestone in treating opioid-exposed newborns! #Prapela #neonatalcare #medtech
Excited to share that John Konsin, CEO & Co-Founder, will be interviewed by John Parker, VP, Board of Trustees of the Charles H. Hood Foundation, to share the Prapela Story at MIT-Hood Pediatric Innovation 2025 on October 23rd!
#PediatricInnovation #Prapela #MIT #HealthTech #HoodFoundation
#PediatricInnovation #Prapela #MIT #HealthTech #HoodFoundation
October 16, 2025 at 5:58 PM
Excited to share that John Konsin, CEO & Co-Founder, will be interviewed by John Parker, VP, Board of Trustees of the Charles H. Hood Foundation, to share the Prapela Story at MIT-Hood Pediatric Innovation 2025 on October 23rd!
#PediatricInnovation #Prapela #MIT #HealthTech #HoodFoundation
#PediatricInnovation #Prapela #MIT #HealthTech #HoodFoundation
Neonatal Abstinence Syndrome (NAS) continues to increase in some areas, declining in others. To solve a problem, you must first measure. As the only FDA-authorized treatment to help these newborns, Prapela acknowledges California's ongoing monitoring efforts.
www.cdph.ca.gov/Programs/CFH...
www.cdph.ca.gov/Programs/CFH...
September 9, 2025 at 3:21 PM
Neonatal Abstinence Syndrome (NAS) continues to increase in some areas, declining in others. To solve a problem, you must first measure. As the only FDA-authorized treatment to help these newborns, Prapela acknowledges California's ongoing monitoring efforts.
www.cdph.ca.gov/Programs/CFH...
www.cdph.ca.gov/Programs/CFH...
This Wednesday, Prapela will be part of the Midwest Pediatric Device Consortium Showcase Event.
We owe a great deal to Ohio's pediatric community, as well as the State of Ohio. On August 27, 2019, the $1M award we received from the Ohio Opioid Technology Challenge.
We owe a great deal to Ohio's pediatric community, as well as the State of Ohio. On August 27, 2019, the $1M award we received from the Ohio Opioid Technology Challenge.
July 7, 2025 at 5:12 PM
This Wednesday, Prapela will be part of the Midwest Pediatric Device Consortium Showcase Event.
We owe a great deal to Ohio's pediatric community, as well as the State of Ohio. On August 27, 2019, the $1M award we received from the Ohio Opioid Technology Challenge.
We owe a great deal to Ohio's pediatric community, as well as the State of Ohio. On August 27, 2019, the $1M award we received from the Ohio Opioid Technology Challenge.
Our visit to Capitol Hill was a success. Our thanks go to Senator Angus King's team for their warm reception. We are excited to be able to help clinicians improve the treatment of opioid-exposed newborns.
June 16, 2025 at 5:50 PM
Our visit to Capitol Hill was a success. Our thanks go to Senator Angus King's team for their warm reception. We are excited to be able to help clinicians improve the treatment of opioid-exposed newborns.
We're on Capitol Hill today. Sharing our first and only FDA-authorized treatment for opioid-exposed newborns with Congress. NIH funding helped make our breakthrough a reality. www.einpresswire.com/article/8205...
Prapela’s FDA-Authorized Groundbreaking Therapy for Opioid-Exposed Infants Highlighted at Washington DC Showcase Event
Prapela, Inc. joins America's leading MedTech corporations at AdvaMed’s prestigious Capitol Hill event.
www.einpresswire.com
June 11, 2025 at 1:44 PM
We're on Capitol Hill today. Sharing our first and only FDA-authorized treatment for opioid-exposed newborns with Congress. NIH funding helped make our breakthrough a reality. www.einpresswire.com/article/8205...
Since 1973, swinging beds, bouncing chairs, and swaying cribs have failed to gain FDA clearance to treat newborns. These products are not supported by rigorous clinical evidence, can't be disinfected, and use habit-forming motions. Prapela is proud to be the first FDA-authorized device for babies.
May 7, 2025 at 5:12 PM
Since 1973, swinging beds, bouncing chairs, and swaying cribs have failed to gain FDA clearance to treat newborns. These products are not supported by rigorous clinical evidence, can't be disinfected, and use habit-forming motions. Prapela is proud to be the first FDA-authorized device for babies.
We are so happy to be able to help the most vulnerable victims of our opioid epidemic.
April 17, 2025 at 3:28 PM
We are so happy to be able to help the most vulnerable victims of our opioid epidemic.
Special thanks to Donald Ingber, M.D., Ph.D. for recognizing @prapela.bsky.social
during his opening address at today’s annual retreat for the Wyss Institute at Harvard University.
during his opening address at today’s annual retreat for the Wyss Institute at Harvard University.
April 11, 2025 at 1:37 PM
Special thanks to Donald Ingber, M.D., Ph.D. for recognizing @prapela.bsky.social
during his opening address at today’s annual retreat for the Wyss Institute at Harvard University.
during his opening address at today’s annual retreat for the Wyss Institute at Harvard University.
Delighted to share our progress helping newborns with the Bernstein Life Sciences & Healthcare Study Group in Boston.
March 12, 2025 at 2:17 PM
Delighted to share our progress helping newborns with the Bernstein Life Sciences & Healthcare Study Group in Boston.
On this World Prematurity Day, Prapela thanks the US National Institutes of Health, especially
The National Institute on Drug Abuse (NIDA), Leonardo M. Angelone and Stacie Gutowski, Ph.D. for supporting our initiative to improve the treatment of apnea of prematurity (AOP).
The National Institute on Drug Abuse (NIDA), Leonardo M. Angelone and Stacie Gutowski, Ph.D. for supporting our initiative to improve the treatment of apnea of prematurity (AOP).
November 17, 2024 at 4:57 PM
On this World Prematurity Day, Prapela thanks the US National Institutes of Health, especially
The National Institute on Drug Abuse (NIDA), Leonardo M. Angelone and Stacie Gutowski, Ph.D. for supporting our initiative to improve the treatment of apnea of prematurity (AOP).
The National Institute on Drug Abuse (NIDA), Leonardo M. Angelone and Stacie Gutowski, Ph.D. for supporting our initiative to improve the treatment of apnea of prematurity (AOP).